RxDoctor Payments Data

Russell Hoffman

Acute Care · Cincinnati, OHNPI 1346284221

Payments from drug & device makers

$1,458in general payments, 2019–2025

Across 60 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$456
  • E.r. Squibb & Sons, L.L.C.$307
  • Sanofi$240
  • Novartis$200
  • Atricure, Inc.$71
  • Boehringer Ingelheim$61
  • plus $124 from 7 others

What the payments were for

  • Food & beverage$1,458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,458 in reported general payments places this provider in the 80th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$25,086
Medicare patients
180
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan575$606,572
VyndamaxTafamidis25$553,416
JardianceEmpagliflozin330$312,961
CamzyosMavacamten35$281,322
EliquisApixaban109$104,162
FarxigaDapagliflozin Propanediol94$83,210
XareltoRivaroxaban34$29,147
Repatha PushtronexEvolocumab32$19,276
VascepaIcosapent Ethyl25$15,405
Repatha SureclickEvolocumab17$14,879
Praluent PenAlirocumab13$11,085
Eplerenone136$10,293
Torsemide275$5,165
Metoprolol Succinate392$4,756
Isosorbide Dinitrate52$2,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$200$606,572575 claims
Boehringer IngelheimJardiance$61$312,961330 claims
E.r. Squibb & Sons, L.L.C.Camzyos$307$281,32235 claims
AstraZenecaFarxiga$12$83,21094 claims
Johnson & JohnsonXarelto$13$29,14734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,101 acute care providers in Ohio.

Other acute care in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →